This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove 2030 Remove Dosage Remove Pharmaceutical Companies Related Topics
Compounding Pharmaceutical Companies More Related Topics >
article thumbnail

OSD contract manufacturing market valued at $54.7 billion by 2030

European Pharmaceutical Review

OCTOBER 7, 2022

A market report has projected that the global oral solid dosage (OSD) contract manufacturing market is expected to be worth $54.7 billion by 2030, displaying a compound annual growth rate (CAGR) of 6.0 Leading companies in the oral solid dosage market are Catalent, Inc.,

Dosage 85
Dosage Compounding Pharmaceutical Companies Pharmaceutical Companies 85
article thumbnail

France gets new sterile liquid drug manufacturing facility

European Pharmaceutical Review

FEBRUARY 3, 2023

Positively, it comes at a time when securing fill finish capacity can be a challenge for many pharmaceutical companies. The HPAPI market A 2022 market report showed that due to the small volumes required for dosage, small-scale providers are also gaining importance. HPAPI contract manufacturing to value $14.6

Dosage 92
Dosage Compounding Pharmaceutical Companies Pharmaceutical Companies 92
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 18,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024